Skip to content

Book an appointment

Click here to book a Covid vaccination appointment

downloads

Covid-19 – Enhanced Service Spec – 16th September 2021

Covid-19 – Enhanced Service Spec – 12th March 2021

Covid-19 – Enhanced Service Spec – 1st December 2020

Covid-19 – Vaccination agreement – 4th December 2020

Covid-19 – Legal mechanisms – 2nd December 2020

COVID19 vaccination programme guidance -29th April 2021

COVID19 Vaccine Deployment in Community Settings

PCN sites – Beginning Covid-19 vaccination

Managing Covid-19 Vaccination Incidents and Enquiries

Covid-19 collaboration agreement

Guidance for vaccinating immunosuppressed individuals with a third dose

clinical cohorts

  1. Residents in a care home for older adults and their carers
  2. All those 80 years of age and over and frontline health and social care workers
  3. All those 75 years of age and over
  4. All those 70 years of age and overand clinically extremely vulnerable individuals
  5. All those 65 years of age and over
  6. All individuals aged 16 to 64 years with underlying health conditions which confer higher risk of serious disease and mortality
  7. All those 60 years of age and over
  8. All those 55 years of age and over
  9. All those 50 years of age and over
  10. All those 40 years of age and over
  11. All those 30 years of age and over
  12. All those 18 years of age and over

Pfizer/BioNTech vaccine

(Comirnaty)

The Pfizer/BioNTech vaccine is a lipid nanoparticle-formulated mRNA vaccine. The mRNA encodes the SARS-CoV-2 full length spike protein. The mRNA in the vaccine is translated and transcribed by the body to produce the spike protein. The protein then acts as an intracellular antigen to stimulate the immune response. The mRNA in the vaccine is normally degraded within a few days and cannot incorporate into the host genome. Data from the Pfizer/BioNTech vaccine trials undertaken in over 40,000 individuals indicate high vaccine efficacy, with no serious safety concerns observed.

C1389-Impact-of-granting-a-Conditional-Marketing-Authorisation-for-Pfizer-BioNTech-COVID-19-vaccine-Comirnaty

AstraZeneca vaccine

 

AstraZeneca COVID-19 vaccine uses a replication deficient chimpanzee adenovirus as a vector that encodes the full-length SARS-CoV2 spike protein. Chimpanzee adenoviruses are non-enveloped viruses, meaning that the glycoprotein antigen is not present on the surface of the vector, but is only expressed at high levels once the vector enters the target cells. Genes are inserted to render the virus replication incompetent, and to enhance immunogenicity. Once the vector is in the nucleus, mRNA encoding the spike protein is produced that then enters the cytoplasm. This leads to translation of the target protein which acts as an intracellular antigen. Headline data from vaccine trials undertaken indicate high vaccine efficacy, with no serious safety events related to the vaccine.

Astra Zeneca Vaccine Protocol

Patient Group Direction Astra Zeneca Vaccine

MHRA and JCVI advice – FAQs

Moderna  vaccine

 

The pharmaceutical form of this medicine is a dispersion for injection and the route of administration is intramuscular injection. COVID 19 Vaccine Moderna will be given to you by an authorised practitioner as an intramuscular injection into the muscle at the top of the upper arm (deltoid muscle).

You will receive 2 injections of COVID 19 Vaccine Moderna, each of 0.5ml. It is recommended to administer the second dose 28 days after the first.

For further information on how COVID-19 Vaccine Moderna is used, refer to the Information for UK recipients on COVID-19 Vaccine Moderna and Information for Healthcare Professionals on COVID-19 Vaccine Moderna available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

 

Moderna Protocol

Moderna Patient Group Directive

Call Now Button